183 related articles for article (PubMed ID: 19734850)
1. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
[TBL] [Abstract][Full Text] [Related]
2. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
[TBL] [Abstract][Full Text] [Related]
3. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
Migliaccio I; Wu MF; Gutierrez C; Malorni L; Mohsin SK; Allred DC; Hilsenbeck SG; Osborne CK; Weiss H; Lee AV
Breast Cancer Res Treat; 2010 Oct; 123(3):651-60. PubMed ID: 19924529
[TBL] [Abstract][Full Text] [Related]
4. High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.
Ye F; Jin P; Cai X; Cai P; Cai H
Med Sci Monit; 2017 Dec; 23():6033-6041. PubMed ID: 29263314
[TBL] [Abstract][Full Text] [Related]
5. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.
Hjelm B; Brennan DJ; Zendehrokh N; Eberhard J; Nodin B; Gaber A; Pontén F; Johannesson H; Smaragdi K; Frantz C; Hober S; Johnson LB; Påhlman S; Jirström K; Uhlen M
Proteomics Clin Appl; 2011 Dec; 5(11-12):624-35. PubMed ID: 21956899
[TBL] [Abstract][Full Text] [Related]
6. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
[TBL] [Abstract][Full Text] [Related]
8. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
9. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
10. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
11. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
12. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.
Sand-Dejmek J; Ehrnström R; Berglund P; Andersson T; Ryden L
PLoS One; 2013; 8(8):e70890. PubMed ID: 23990917
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
15. C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.
Hilborn E; Sivik T; Fornander T; Stål O; Nordenskjöld B; Jansson A
Breast Cancer Res Treat; 2014 May; 145(1):73-82. PubMed ID: 24715380
[TBL] [Abstract][Full Text] [Related]
16. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Brennan DJ; Laursen H; O'Connor DP; Borgquist S; Uhlen M; Gallagher WM; Pontén F; Millikan RC; Rydén L; Jirström K
Breast Cancer Res; 2011 Jan; 13(1):R12. PubMed ID: 21281480
[TBL] [Abstract][Full Text] [Related]
18. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Ross DT; Kim CY; Tang G; Bohn OL; Beck RA; Ring BZ; Seitz RS; Paik S; Costantino JP; Wolmark N
Clin Cancer Res; 2008 Oct; 14(20):6602-9. PubMed ID: 18927301
[TBL] [Abstract][Full Text] [Related]
20. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
